VIEMED HEALTHCARE, INC. 10-Q

Item 1. Financial Statements VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Expressed in thousands of U.S. Dollars, except outstanding shares) Note At September 30, 2025 At December 31, 2024 (Unaudited) (Audited) ASSETS Current assets Cash and cash equivalents 2 $ 11,123 $ 17,540 Accounts receivable, net 2 27,414 24,911 Inventory 2 5,269 4,320 Income tax receivable 1,913 — Prepaid expenses and other assets 4,265 6,109 Total current assets $ 49,984 $ 52,880 Long-term assets Property and equipment, net 4 80,512 76,279 Finance lease right-of-use assets — 50 Operating lease right-of-use assets 3,589 2,831 Equity investments 2 2,794 2,794 Deferred tax asset 10 5,669 8,398 Identifiable intangibles, net 1,348 848 Goodwill 3 58,464 32,989 Total long-term assets $ 152,376 $ 124,189 TOTAL ASSETS $ 202,360 $ 177,069 LIABILITIES Current liabilities Trade payables $ 8,670 $ 5,322 Deferred revenue 7,810 6,694 Income taxes payable — 3,883 Accrued liabilities 5 25,007 20,157 Finance lease liabilities, current portion 6 — 50 Operating lease liabilities, current portion 6 1,149 811 Current portion of long-term debt 6 1,554 409 Total current liabilities $ 44,190 $ 37,326 Long-term liabilities Accrued liabilities 8 680 846 Operating lease liabilities, less current portion 6 2,410 2,007 Long-term debt 6 19,585 3,589 Total long-term liabilities $ 22,675 $ 6,442 TOTAL LIABILITIES $ 66,865 $ 43,768 Commitments and Contingencies — — SHAREHOLDERS' EQUITY Common stock - No par value: unlimited authorized; 38,017,907 and 39,132,897 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 8 $ 16,901 $ 23,365 Additional paid-in capital 19,453 18,337 Retained earnings 97,254 89,691 TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY $ 133,608 $ 131,393 Noncontrolling interest in subsidiary 3 1,887 1,908 TOTAL SHAREHOLDERS' EQUITY 135,495 133,301 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 202,360 $ 177,069 See accompanying notes to the condensed consolidated financial statements Page 3 VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Expressed in thousands of U.S. Dollars, except share and per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, Note 2025 2024 2025 2024 Revenue 2 $ 71,914 $ 58,004 $ 194,099 $ 163,562 Cost of revenue 30,569 23,633 82,744 66,497 Gross profit $ 41,345 $ 34,371 $ 111,355 $ 97,065 Operating expenses Selling, general and administrative 31,919 26,671 89,147 77,988 Research and development 775 757 2,419 2,265 Stock-based compensation 8 2,180 1,712 6,832 4,764 Depreciation and amortization 397 348 1,098 1,140 Loss (gain) on disposal of property and equipment 476 ( 469 ) ( 2,528 ) ( 801 ) Other expense (income), net ( 44 ) ( 276 ) ( 191 ) 261 Income from operations $ 5,642 $ 5,628 $ 14,578 $ 11,448 Non-operating income and expenses Income (loss) from investments — 96 — ( 954 ) Interest expense, net 6 ( 507 ) ( 225 ) ( 818 ) ( 629 ) Net income before taxes 5,135 5,499 13,760 9,865 Provision for income taxes 10 1,535 1,594 4,200 2,880 Net income $ 3,600 $ 3,905 $ 9,560 $ 6,985 Net income attributable to noncontrolling interest 87 27 265 36 Net income attributable to Viemed Healthcare, Inc. $ 3,513 $ 3,878 $ 9,295 $ 6,949 Net income per share Basic 11 $ 0.09 $ 0.10 $ 0.24 $ 0.18 Diluted 11 $ 0.09 $ 0.10 $ 0.23 $ 0.17 Weighted average number of common shares outstanding: Basic 11 38,638,660 38,870,823 39,190,666 38,803,887 Diluted 11 40,495,761 40,779,414 41,086,178 40,702,001 See accompanying notes to the condensed consolidated financial statements Page 4 VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Expressed in thousands of U.S. Dollars, except share and per share amounts) (Unaudited) Common Stock Additional paid-in capital Noncontrolling interest in subsidiary Total Shareholders' equity Shares Amount Retained earnings Shareholders' equity, December 31, 2023 38,506,161 $ 18,702 $ 15,698 $ 79,495 $ — $ 113,895 Stock-based compensation - options — — 111 — — 111 Stock-based compensation - restricted stock — — 1,321 — — 1,321 Exercise of options 60,130 304 — — — 304 Shares issued for vesting of restricted stock units 378,837 2,836 ( 2,836 ) — — — Shares redeemed to pay income tax ( 128,362 ) — — ( 961 ) — ( 961 ) Net income — — — 1,603 — 1,603 Shareholders' equity, March 31, 2024 38,816,766 $ 21,842 $ 14,294 $ 80,137 $ — $ 116,273 Stock-based compensation - options — — 59 — — 59 Stock-based compensation - restricted stock — — 1,561 — — 1,561 Exercise of options 4,000 21 — — — 21 Shares issued for vesting of restricted stock units 6,654 47 ( 47 ) — — — Shares redeemed to pay income tax ( 1,621 ) — — ( 11 ) — ( 11 ) Acquired noncontrolling interest — — — — 1,800 1,800 Net income — — — 1,468 9 1,477 Shareholders' equity, June 30, 2024 38,825,799 $ 21,910 $ 15,867 $ 81,594 $ 1,809 $ 121,180 Stock-based compensation - options — — 61 — — 61 Stock-based compensation - restricted stock — — 1,651 — — 1,651 Exercise of options 17,516 91 — — — 91 Shares issued for vesting of restricted stock units 101,438 748 ( 748 ) — — — Shares redeemed to pay income tax ( 12,506 ) — — ( 93 ) — ( 93 ) Net income — — — 3,878 27 3,905 Shareholders' equity, September 30, 2024 38,932,247 $ 22,749 $ 16,831 $ 85,379 $ 1,836 $ 126,795 See accompanying notes to the condensed consolidated financial statements Page 5 VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Expressed in thousands of U.S. Dollars, except share and per share amounts) (Unaudited) Common Stock Additional paid-in capital Noncontrolling interest in subsidiary Total Shareholders' equity Shares Amount Retained earnings Shareholders' equity, December 31, 2024 39,132,897 $ 23,365 $ 18,337 $ 89,691 $ 1,908 $ 133,301 Stock-based compensation - options — — 16 — — 16 Stock-based compensation - restricted stock — — 2,295 — — 2,295 Exercise of options 2,225 11 — — — 11 Shares issued for vesting of restricted stock units 581,838 4,775 ( 4,775 ) — — — Shares redeemed to pay income tax ( 193,173 ) — — ( 1,584 ) — ( 1,584 ) Net income — — — 2,625 85 2,710 Shareholders' equity, March 31, 2025 39,523,787 $ 28,151 $ 15,873 $ 90,732 $ 1,993 $ 136,749 Stock-based compensation - options — — 6 — — 6 Stock-based compensation - restricted stock — — 2,335 — — 2,335 Exercise of options 336,633 1,357 — — — 1,357 Shares issued for vesting of restricted stock units 21,293 145 ( 145 ) — — — Shares redeemed to pay income tax ( 6,647 ) — — ( 47 ) — ( 47 ) Distribution to non-controlling interest — — — — ( 193 ) ( 193 ) Shares repurchased under the share repurchase program ( 270,061 ) ( 1,866 ) 33 — — ( 1,833 ) Net income — — — 3,157 93 3,250 Shareholders' equity, June 30, 2025 39,605,005 $ 27,787 $ 18,102 $ 93,842 $ 1,893 $ 141,624 Stock-based compensation - options — — 3 — — 3 Stock-based compensation - restricted stock — — 2,177 — — 2,177 Exercise of options 13,965 71 — — — 71 Shares issued for vesting of restricted stock units 119,569 834 ( 834 ) — — — Shares redeemed to pay income tax ( 14,252 ) — — ( 101 ) — ( 101 ) Distribution to non-controlling interest — — — — ( 93 ) ( 93 ) Shares repurchased under the share repurchase program ( 1,706,380 ) ( 11,791 ) 5 — — ( 11,786 ) Net income — — — 3,513 87 3,600 Shareholders' equity, September 30, 2025 38,017,907 $ 16,901 $ 19,453 $ 97,254 $ 1,887 $ 135,495 See accompanying notes to the condensed consolidated financial statements Page 6 VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Expressed in thousands of U.S. Dollars) (Unaudited) Nine Months Ended September 30, Note 2025 2024 Cash flows from operating activities Net income $ 9,560 $ 6,985 Adjustments for: Depreciation and amortization 21,043 19,002 Stock-based compensation expense 8 6,832 4,764 Distributions of earnings received from equity method investments — 147 Income from equity method investments — ( 261 ) Loss from debt investment — 1,344 Gain on disposal of property and equipment ( 2,528 ) ( 801 ) Amortization of deferred financing costs 121 135 Deferred income tax expense (benefit) 2,729 ( 3,507 ) Changes in working capital: Accounts receivable, net ( 670 ) ( 8,213 ) Inventory ( 163 ) 583 Prepaid expenses and other assets ( 626 ) 340 Trade payables 767 747 Deferred revenue 622 489 Accrued liabilities 1,584 2,424 Income tax payable/receivable ( 5,796 ) ( 76 ) Net cash provided by operating activities $ 33,475 $ 24,102 Cash flows from investing activities Purchase of property and equipment ( 31,248 ) ( 25,942 ) Cash paid for acquisitions, net of cash acquired 3 ( 26,332 ) ( 2,999 ) Proceeds from sale of property and equipment 4 15,026 7,440 Net cash used in investing activities $ ( 42,554 ) $ ( 21,501 ) Cash flows from financing activities Proceeds from exercise of options 8 1,439 416 Proceeds from term notes 6 9,000 — Principal payments on term notes 6 ( 484 ) ( 954 ) Proceeds from revolving credit facilities 6 13,000 3,000 Payments on revolving credit facilities 6 ( 5,000 ) ( 5,000 ) Payments for debt issuance costs — ( 171 ) Shares redeemed to pay income tax 8 ( 1,732 ) ( 1,065 ) Shares repurchased under the share repurchase program 8 ( 13,225 ) — Repayments of finance lease liabilities ( 50 ) ( 319 ) Distributions to non-controlling interest ( 286 ) — Net cash provided by (used in) financing activities $ 2,662 $ ( 4,093 ) Net decrease in cash and cash equivalents ( 6,417 ) ( 1,492 ) Cash and cash equivalents at beginning of year 17,540 12,839 Cash and cash equivalents at end of period $ 11,123 $ 11,347 Supplemental disclosures of cash flow information Cash paid during the period for interest $ 587 $ 745 Cash paid during the period for income taxes, net of refunds $ 7,267 $ 6,416 Supplemental disclosures of non-cash transactions Equipment and other fixed asset purchases payable at end of period $ 4,774 $ 2,854 Equipment sales receivable at end of period $ — $ 1,683 See accompanying notes to the condensed consolidated financial statements Page 7 VIEMED HEALTHCARE, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts) (Unaudited) 1. Nature of Business and Operations Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute respiratory healthcare services in the United States. The Company’s primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company serves patients in all 50 states of the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508. The Company’s common shares are traded on the Nasdaq Capital Market under the symbol "VMD". 2. Summary of Significant Accounting Policies Principles of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. The Company's fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of September 30, 2025 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of the Company's independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. Prior to December 31, 2024, the Company qualified as an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, as modified by the Jumpstart our Business Startups Act of 2012, and took advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and other exemptions. As of December 31, 2024, the Company no longer qualified as an emerging growth company, and as a result is no longer exempt from the reporting requirements discussed above. Reporting Currency All values are in U.S. dollars ($ or "USD"). Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts. Basis of Consolidation These consolidated financial statements include the accounts of the Company and its subsidiaries in which it has a controlling financial interest. All intercompany transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable, income tax provisions, the fair value of financial instruments, and goodwill. Actual results could differ from these estimates. Page 8 Segment Reporting The Company’s chief operating decision-makers ("CODMs") are its Chief Executive Officer and Chief Operating Officer, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure. All expense categories on the Condensed Consolidated Statements of Income are significant and there are no other significant segment expenses that require disclosure. Accounts Receivable Accounts receivable and revenues are based on contractually agreed-upon rates for services provided, reduced by estimated adjustments. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of adjustments, including variable consideration for implicit price concessions related to sales revenues and an estimate for probable losses related to net rental revenues. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations governing Medicare and Medicaid may result in adjustments to amounts originally recorded. The Company performs a periodic analysis to review the valuation of accounts receivable and collectability of outstanding balances. These estimates are determined utilizing historical realization data under a portfolio approach, which is then assessed by management to evaluate whether adjustments should be made based on accounts receivable aging trends, other operating trends, and relevant business conditions such as governmental and managed care payor claims processing procedures. The Company records a reserve for estimated probable losses as part of rental revenue adjustments in order to report rental revenue at an expected collectable amount based on the total portfolio of operating lease receivables for which collectability has been deemed probable. Receivables are considered past due when not collected by established due dates. Specific patient balances are written off after collection efforts have been followed and the account has been determined to be uncollectible. Revisions in reserve estimates are recorded as an adjustment to revenue in the period of revision. Included in accounts receivable at September 30, 2025 are amounts due from Medicare representing 27 % of total outstanding net receivables. As of December 31, 2024, 27 % of total outstanding net receivables were amounts due from Medicare. Inventory Inventory represents non-serialized supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value. Property and Equipment Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Page 9 Equity Investments Equity investments on the Condensed Consolidated Balance Sheets are primarily comprised of equity investments without readily determinable fair values accounted for under the measurement alternative described in ASC 321-10-35-2. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The balance of the Company’s equity investments was $ 2.8 million as of September 30, 2025 and December 31, 2024. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of September 30, 2025 on its investments in equity securities without a readily determinable fair value. Intangible Assets Intangible assets include trade names and other identifiable intangible assets. Amortization expense related to definite lived identifiable intangible assets is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Income. Revenue Recognition Revenues are principally derived from the rental and sale of HME products and services to patients. Rental revenues Revenue generated from equipment that is rented to patients is recognized over the non-cancellable rental period (typically one month) and commences on delivery of the equipment to the patients. The agreements are evaluated at commencement and the start of each monthly renewal period to determine if it is reasonably certain that the monthly renewal or purchase options would be exercised. The exercise of monthly renewal or purchase options by a patient has historically not been reasonably certain to occur at lease commencement or subsequent monthly renewals. Revenues are recorded at amounts estimated to be received under reimbursement arrangements with payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. Rental revenue, less estimated adjustments, is recognized as earned on a straight-line basis over the non-cancellable lease term. Rental of patient equipment is billed on a monthly basis beginning on the date the equipment is delivered. Since deliveries can occur on any day during a month, the amount of billings that apply to the next month are deferred. The Company's lease agreements generally contain lease components and non-lease components, which primarily relate to supplies. The Company has made the accounting policy election to account for a lease component of an agreement and its associated non-lease components as a single lease component based on the Company's assessment of classification of the lease based on the consideration in the contract for the combined component. Sales and Services revenues Revenue related to sales of equipment and supplies is recognized on the date of delivery as this is when control of the promised goods is transferred to patients and is presented net of applicable sales taxes. Revenues are recorded only to the extent it is probable that a significant reversal will not occur in the future as amounts may include implicit price concessions under reimbursement arrangements with payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. The sales transaction price is determined based on contractually agreed-upon rates, adjusted for estimates of variable consideration. The expected value method is used in determining the variable consideration as part of determining the sales transaction price using historical reimbursement experience, historical sales returns, and other operating trends. Payment terms and conditions vary by contract. The timing of revenue recognition, billing, and cash collection generally results in billed and unbilled accounts receivable. Revenues associated with external staffing services are accrued on an hourly basis and are recorded based on the determination of whether the Company is acting as a principal or an agent. In arrangements in which the Company manages customers' supplemental workforce needs utilizing its own network of healthcare professionals, the Company is determined to be a principal and includes the contractual gross billings in revenues with a corresponding increase to cost of revenues for worksite employee payroll costs associated with these services. Alternatively, when the Company acts as agent in the performance of workforce management, revenue is recorded based on contractually agreed upon fees or commissions with no associated cost of revenues. Page 10 The revenues from each major source are summarized in the following table: Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue from rentals Ventilator rentals, non-invasive and invasive $ 34,883 $ 31,772 $ 100,862 $ 91,404 Other home medical equipment rentals 15,401 12,459 42,199 35,604 Revenue from sales and services Equipment and supply sales 15,700 8,440 32,720 21,956 Service revenues 5,930 5,333 18,318 14,598 Total revenues $ 71,914 $ 58,004 $ 194,099 $ 163,562 Revenues from Medicare as a percentage of the Company's total revenue for the nine months ended September 30, 2025 and 2024 were 39 % and 44 %, respectively. Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with ASC 718 , "Compensation—Stock Compensation" , which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. For the Company’s phantom share units ("PSUs") settled in cash, the Company computes the fair value of the PSUs using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service. Income Taxes The Company is subject to income taxes in numerous U.S. jurisdictions. The Company's income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company's effective tax rate as well as the Company's business and operations. Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense. Deferred tax is recognized on any temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable earnings. The effect of a change in the enacted tax rates is recognized in net earnings and comprehensive income or in equity depending on the item to which the adjustment relates. At each reporting period end, deferred tax assets are evaluated for recoverability based on whether it is more likely than not that sufficient taxable earnings will be available to allow all or part of the asset to be recovered. Page 11 Business Combinations The Company applies the acquisition method of accounting for business acquisitions. The results of operations of the business acquired by the Company are included as of the respective acquisition date. The acquisition-date fair value of the consideration transferred, including the fair value of any contingent consideration, is allocated to the underlying assets acquired, liabilities assumed, and noncontrolling interest in the acquiree based upon their estimated fair values at the date of acquisition. To the extent the acquisition-date fair value of the consideration transferred exceeds the fair value of the identifiable tangible and intangible assets acquired, liabilities assumed, and any noncontrolling interests, such excess is allocated to goodwill. Patient relationships, medical records and patient lists are not reported as separate intangible assets due to the regulatory requirements and lack of contractual agreements but are part of goodwill. Customer related relationships are not reported as separate intangible assets but are part of goodwill as authorizing physicians are under no obligation to refer the Company’s services to their patients, who are free to change physicians and service providers at any time. The Company may adjust the preliminary purchase price allocation, as necessary, as it obtains more information regarding asset valuations and liabilities assumed that existed but were not available at the acquisition date, which is generally up to one year after the acquisition closing date. Acquisition related costs are recognized separately from the business combination and are expensed as incurred. Impairment of Goodwill and Long-Lived Assets Goodwill resulting from business combinations is not amortized, rather, it is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors, such as estimates of a reporting unit's fair value and judgment about impairment triggering events. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual or interim goodwill impairment test will prove to be accurate predictions of the future. For the year ended December 31, 2024, the Company performed an assessment of qualitative factors and determined that no events or circumstances existed that would lead to a determination that it is more likely than not that the fair value of indefinite-lived assets were less than the carrying amount. As such, a quantitative analysis was not required to be performed and the Company did not record any goodwill impairment charges. The Company follows ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the asset group’s carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale, they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. There were no impairment charges recognized during the nine months ended September 30, 2025 and September 30, 2024. Net Income per Share Attributable to Viemed Healthcare, Inc.'s Common Stockholders Basic net income per share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net income per common share is computed based on the weighted average number of shares of common stock plus the effect of dilutive stock-based awards outstanding during the period using the treasury stock method. Dilutive stock-based awards include outstanding common stock options and time-based RSUs. See Note 11 for earnings per share computations. Page 12 Recently Adopted Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company adopted this standard during the year ended December 31, 2024, which did not have a material impact on its consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements In December 2023, the FASB issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which is intended to improve the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid by jurisdiction. The ASU is effective for public business entities' annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this pronouncement and is evaluating the impact it will have on its upcoming annual filing on Form 10-K for the year ended December 31, 2025; however, the Company currently does not believe the adoption will have a material impact on its consolidated financial statements and disclosures for that Form 10-K filing. In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (DISE) , which specifies additional disclosure requirements. The new guidance requires additional disclosures, including the composition of certain income expense line items (such as purchases of inventory, employee compensation, and 'other expenses') and a separate disclosure for selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, however, early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. In September 2025, the FASB issued ASU No. 2025-06, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40) , which amends certain aspects of the accounting and disclosure requirements for internal-use software costs. The amendments remove references to software project development stages and provide updated guidance for assessing whether the probable-to-complete threshold for capitalization has been met. The ASU is effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual periods. Early adoption is permitted. The amendments may be applied prospectively, retrospectively, or using a modified prospective approach. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements and related disclosures. Page 13 3. Business Combinations Lehan Drugs, Inc On July 1, 2025, the Company completed the acquisition of 100 % of the outstanding equity interests of Lehan Drugs, Inc. (“Lehan”), an Illinois-based provider of home medical equipment. The acquisition met the definition of a business and was accounted for under the acquisition method of accounting in accordance with ASC 805. The fair value of the consideration totaled approximately $ 28.7 million. The following table summarizes the estimated fair values of the consideration paid or payable, assets acquired, and liabilities assumed at the acquisition date (in thousands): Purchase Price Cash paid or payable $ 26,921 Contingent consideration 1,750 TOTAL CONSIDERATION 28,671 Identifiable Assets Cash and cash equivalents 383 Accounts receivable 1,833 Inventory 786 Prepaid expenses and other assets 176 Property and equipment, net 959 Lease assets 60 Identifiable intangibles 628 TOTAL ASSETS 4,825 Identifiable Liabilities Trade payables 490 Deferred revenue 494 Accrued liabilities 586 Current portion of lease liabilities 41 Long-term lease liabilities 18 TOTAL LIABILITIES 1,629 Net assets acquired 3,196 Resulting goodwill $ 25,475 The purchase price allocation remains preliminary as the Company is in the process of finalizing third-party valuations of certain tangible and intangible assets, as well as determining the final net working capital adjustment. Accordingly, the amounts reported above are subject to change during the measurement period, which will not exceed 12 months from the acquisition date. The results of Lehan’s operations have been included in the Company’s condensed consolidated financial statements since the acquisition date. The Company incurred approximately $ 1.0 million of acquisition-related costs during the nine months ended September 30, 2025, which are included in selling, general and administrative expenses. Goodwill recognized in this transaction primarily represents the expected realization of operational synergies, the integration of Lehan’s maternal health services within Viemed’s broader clinical platform, and the strategic expansion of the Company’s geographic presence across the Midwest. All goodwill is expected to be deductible for income tax purposes. Page 14 East Alabama HomeMed, LLC On April 1, 2024, the Company acquired a controlling 60 % equity interest in East Alabama HomeMed, LLC ("HomeMed"). The acquisition was accounted for under the acquisition method of accounting in accordance with ASC 805. As a result of the acquisition, goodwill of $ 3.2 million and a trade name of $ 0.4 million were recognized. The Company determined that its portion of the goodwill is fully tax-deductible. Additionally, a noncontrolling interest of $ 1.8 million was recorded at the acquisition date. The accompanying financial statements include the results of HomeMed's operations from the acquisition date. Changes in the noncontrolling interests after the acquisition date are accounted for pursuant to ASC 810, Consolidation . 4. Property and Equipment The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment. The following table details the Company’s fixed assets: September 30, 2025 December 31, 2024 Medical equipment $ 120,240 $ 116,938 Furniture and equipment 5,176 4,523 Land 2,566 2,566 Buildings 8,483 8,307 Leasehold improvements 717 660 Vehicles 1,423 1,288 Less: Accumulated depreciation ( 58,093 ) ( 58,003 ) Property and equipment, net of accumulated depreciation $ 80,512 $ 76,279 Depreciation in the amount of $ 7.1 million and $ 6.1 million is included in cost of revenue for the three months ended September 30, 2025 and 2024, respectively, and in the amount of $ 19.9 million and $ 17.9 million for the nine months ended September 30, 2025 and 2024, respectively. 5. Current Liabilities The Company’s short-term accrued liabilities are included within current liabilities and consist of the following: September 30, 2025 December 31, 2024 Accrued trade payables $ 5,747 $ 4,016 Accrued commissions payable 1,035 1,027 Accrued bonuses payable 4,594 6,589 Accrued vacation and payroll 5,617 3,402 Current portion of phantom share liability 1,253 1,701 Acquisition-related contingent consideration 1,750 — Accrued other liabilities 5,011 3,422 Total accrued liabilities $ 25,007 $ 20,157 Page 15 6. Debt and Lease Liabilities Debt The following table summarizes the Company’s debt as of September 30, 2025 and December 31, 2024: September 30, 2025 December 31, 2024 2022 Senior Credit Facilities $ 21,113 $ 4,563 Medical equipment financing 504 34 Financing costs and commitment fees ( 478 ) ( 599 ) Current portion ( 1,554 ) ( 409 ) Long-term portion $ 19,585 $ 3,589 2022 Senior Credit Facilities On November 29, 2022, the Company refinanced its existing borrowings under the 2018 Senior Credit Facility and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent (the "Administrative Agent") and collateral agent, that provides for an up to $ 30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $ 30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027. The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions. The interest rates per annum applicable to the 2022 Senior Credit Facilities are a forward looking term rate based on a secured overnight financing rate ("Term SOFR") plus an applicable margin ranging from 2.625 % to 3.375 %, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625 % to 2.375 %. The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following : • Consolidated Total Leverage Ratio ( defined generally as total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii) for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition. • Consolidated Fixed Charge Coverage Ratio ( defined generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25 :1.0. The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at September 30, 2025. The 2022 Senior Credit Facilities include provisions permitting the Company from time to time to, subject to certain terms and conditions, increase the aggregate amount of commitments under the 2022 Revolving Credit Facility and/or establish one or more additional term loans under the 2022 Term Loan Facility, in each case, with additional commitments from existing lenders or new commitments from financial institutions acceptable to the Administrative Agent in its reasonable discretion; provided, that, (a) the aggregate principal amount of any increases in the 2022 Revolving Credit Facility, and (b) the aggregate principal amount of all additional term loans under the 2022 Term Loan Facility established after the closing date will not exceed $ 30.0 million. Page 16 Financing costs related to the 2022 Senior Credit Facilities are capitalized and amortized over the term of the loans using the effective interest method. Upon the initial draw of debt under the 2022 Senior Credit Facilities during the year ended December 31, 2023, the Company reclassified the deferred financing fees previously recorded in other long-term assets to long-term debt in the condensed consolidated balance sheets. On May 28, 2024, the Company entered into a First Amendment to the 2022 Senior Credit Facilities that (a) extended the delayed draw term loan commitment expiration date to November 29, 2025, from its initial expiration date of May 29, 2024, and (b) provided for other technical amendments. On June 6, 2025, the Company entered into a Second Amendment to the 2022 Senior Credit Facilities that (a) increased the permitted amount of restricted payments that may be made by the Company and its subsidiaries subject to specified conditions, and (b) made other conforming and administrative changes. Medical Equipment Financing The Company enters into medical equipment financing obligations through supplier finance programs. The financing obligations are primarily short term in nature and are payable in monthly installments. Leases The Company has recognized finance lease liabilities for vehicles and operating leases for land and buildings that have terms greater than twelve months, as follows: September 30, 2025 December 31, 2024 Lease liabilities $ 3,559 $ 2,868 Less: Current portion of lease liabilities ( 1,149 ) ( 861 ) Net long-term lease liabilities $ 2,410 $ 2,007 Operating Lease Liabilities The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. The exercise of lease renewal options is at the Company's sole discretion and is included in the lease term for calculations of its right-of-use assets and liabilities when it is reasonably certain that the Company plans to renew these leases. These lease liabilities are recorded at present value based on a discount rate ranging from 5.5 % to 7.87 %, based on the Company's incremental borrowing rate at the time of assessment. At September 30, 2025 , the weighted average lease term was approximately 3.30 years. Future maturities of the Company's operating lease liabilities as of September 30, 2025 are summarized as follows: Lease Liability 2025 $ 344 2026 1,360 2027 1,096 2028 861 2029 238 Thereafter 167 Total lease payments $ 4,066 Less: imputed interest 507 Present value of lease liabilities $ 3,559 Operating rental expenses were $ 1.3 million and $ 1.1 million during the nine months ended September 30, 2025 and 2024 , respectively. Page 17 7. Fair Value Measurement Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active. Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company measures certain assets and liabilities at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period. The following tables summarize the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024: At September 30, 2025 (In thousands) Level 1 Level 2 Level 3 Total Assets: Money market mutual funds $ 289 $ — $ — $ 289 Liabilities: Acquisition-related contingent consideration $ — $ — $ 1,750 $ 1,750 At December 31, 2024 (In thousands) Level 1 Level 2 Level 3 Total Assets: Money market mutual funds $ 10,582 $ — $ — $ 10,582 Acquisition-Related Contingent Consideration The Company estimates the fair value of acquisition-related contingent consideration liabilities using the income approach, based on a probability-weighted discounted cash flow model. Because this valuation relies on significant inputs that are not observable in active markets, it is classified as a Level 3 fair value measurement. Level 3 instruments are valued using unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. The Company reassesses the fair value of acquisition-related contingent consideration each reporting period, and any changes in estimated fair value are recognized in Other expense (income) in the Condensed Consolidated Statements of Income. At September 30, 2025, contingent consideration liabilities of $ 1.8 million were included in accrued liabilities in the Condensed Consolidated Balance Sheets. There were no changes in fair value or payments related to contingent consideration during the nine months ended September 30, 2025. At December 31, 2024, the Company had no contingent consideration liabilities. Page 18 Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis The Company measures certain assets at fair value on a nonrecurring basis. These assets include other equity investments and the fair value allocation related to the Company’s acquisitions. The Company's other equity investments are holdings in privately-held companies without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with the measurement alternative under Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings the Company owns. The Company had no material adjustments of other equity investments measured at fair value on a nonrecurring basis during any of the periods presented. The fair value allocation related to the Company’s acquisitions are determined using a discounted cash flow approach, or a replacement cost approach, which are based on significant unobservable inputs (Level 3). These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, replacement costs, and discount rates. The Company’s estimates are based upon historical trends, management’s knowledge and experience and overall economic factors, including projections of future earnings potential. Developing discounted future cash flows in applying the income approach requires the Company to evaluate its intermediate to longer-term strategies, including, but not limited to, estimates of revenue growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows. The Company estimated the fair value of acquired identifiable intangible assets using discounted cash flow techniques that included an estimate of future cash flows, consistent with overall cash flow projections used to determine the purchase price paid to acquire the business, discounted at a rate of return that reflects the relative risk of the cash flows. The Company estimated the fair value of certain acquired identifiable intangible assets based on the cost approach using estimated costs consistent with historical experience. The Company believes the estimates and assumptions used in the valuation methods are reasonable. There were no transfers between fair value measurement levels during any presented period. Page 19 8. Shareholders' Equity Authorized Share Capital The Company’s authorized share capital consists of an unlimited number of common shares, with no stated par value . Issued and Outstanding Share Capital The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 38,017,907 and 39,132,897 shares were issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. For the nine months ended September 30, 2025, the Company repurchased and canceled 1,976,441 common shares at a cost of $ 13.6 million pursuant to the Share Repurchase Program authorized by the Board of Directors on June 6, 2025 (the "2025 Share Repurchase Program"). The Company also acquired and cancelled 214,072 common shares at a cost of $ 1.7 million to satisfy employee income tax withholding associated with RSUs vesting during the nine months ended September 30, 2025. The Company’s equity accounts were reduced by the amount paid for the shares repurchased and cancelled. Stock-Based Compensation On June 6, 2024 (the "Effective Date"), the Company’s shareholders approved the Company's 2024 Long Term Incentive Plan (the "2024 Omnibus Plan") to provide an incentive to attract, retain, and reward directors, officers, employees, and consultants who provide services to the Company or any of its subsidiaries. All directors, officers, employees, and consultants of the Company and/or its affiliates are eligible to receive awards under the 2024 Omnibus Plan, subject to its terms. Awards include common share purchase options, restricted stock, stock appreciation rights, performance awards, or other stock-based awards, including restricted stock units, deferred stock units, and dividends and dividend equivalents. On June 5, 2025, the Company's shareholders approved the first amendment to the 2024 Omnibus Plan, increasing the aggregate number of common shares authorized for issuance. Following this amendment, the maximum number of common shares that will be available for awards and issuance under the 2024 Omnibus Plan and that may be reserved for issuance at any time, including under previous plans such as the 2020 Long Term Incentive Plan (effective June 11, 2020), the Amended and Restated Stock Option Plan (effective as of July 17, 2018), the Amended and Restated Restricted Share Unit Plan (effective as of July 17, 2018), and the Deferred Share Unit Plan (effective July 17, 2018), is 7,904,769 shares. The maximum amount of common shares that may be awarded under the 2024 Omnibus Plan as “incentive stock options” is 1,000,000 common shares. As of September 30, 2025, the Company had outstanding options of 3,538,000 and RSUs of 2,128,000 associated with common shares under the existing plans. The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Stock-based compensation - options $ 3 $ 61 $ 25 $ 231 Stock-based compensation - restricted stock units 2,177 1,651 6,807 4,533 Total $ 2,180 $ 1,712 $ 6,832 $ 4,764 At September 30, 2025, there was no remaining unrecognized pre-tax stock option expense under the Company’s equity compensation plans. As of September 30, 2025, there was approximately $ 8,150,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 1.45 years. Page 20 Options The following table summarizes stock option activity for the nine months ended September 30, 2025: Number of options (000's) Weighted average exercise price (1) Weighted average remaining contractual life Aggregate intrinsic value (2) Balance December 31, 2024 3,917 $ 5.36 5.0 years $ 10,984 Issued — — Exercised ( 353 ) 4.08 Expired / Forfeited ( 26 ) 10.44 Balance September 30, 2025 3,538 $ 5.45 4.4 years $ 6,219 (1) For presentation purposes, stock options issued with a Canadian dollar exercise price have been translated to U.S. dollars based on the prevailing exchange rate on the date of grant. (2) The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing price of the Company's common shares on the last trading day of the period ($ 6.79 and $ 8.02 on September 30, 2025 and December 31, 2024, respectively ). The aggregate intrinsic value of options outstanding and options exercisable was $ 6,219,000 at September 30, 2025. For the nine months ended September 30, 2025, 352,823 common shares were issued pursuant to the exercise of stock options. At September 30, 2025, the Company had 3,538,000 exercisable stock options outstanding with a weighted average exercise price of $ 5.45 and a weighted average remaining contractual life of 4.4 years. At December 31, 2024, the Company had 3,691,000 exercisable stock options outstanding with a weighted average exercise price of $ 5.37 and a weighted average remaining contractual life of 4.9 years . The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and credited to additional paid-in capital over the vesting period, using the grant date fair value based on the Black-Scholes option pricing model. The assumptions used to determine the grant date fair value of stock options include exercise price, risk-free interest rates, expected volatility, and average life of an option. The risk-free interest rates are based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option’s expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on the Company's common shares and historical volatility of the Company's common shares over the expected life of the option. There were no issuances of options during the nine months ended September 30, 2025. Restricted Stock Units The Company accounts for RSUs using fair value. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. RSUs vest generally over a one or three-year period. The Company accounts for forfeitures of RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur. The following table summarizes RSU activity for the nine months ended September 30, 2025: Number of RSUs (000's) Weighted average grant price Weighted average remaining contractual life Aggregate intrinsic value (1) Balance December 31, 2024 1,514 $ 7.80 1.38 years $ 12,141 Issued 1,404 8.05 Vested ( 723 ) 7.44 Forfeited ( 67 ) 7.98 Balance September 30, 2025 2,128 $ 8.08 1.45 years $ 14,449 (1) The aggregate intrinsic value of time-based RSUs outstanding was based on the closing price of the Company's common shares on the last trading day of the period ($ 6.79 and $ 8.02 on September 30, 2025 and December 31, 2024, respectively ). During the nine months ended September 30, 2025, the Company issued 1,404,210 RSUs with a vesting term of one or three years and a weighted-average fair value of $ 8.05 per share. Page 21 Phantom Share Units The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. PSUs granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. PSUs vest generally over a one or three-year period. The cash-settled PSUs are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period. The following table summarizes PSU activity for the nine months ended September 30, 2025: Number of phantom share units (000's) Value of share equivalents (1) Balance December 31, 2024 441 $ 3,537 Issued 272 2,244 Vested ( 215 ) 1,758 Forfeited ( 15 ) ( 105 ) Balance September 30, 2025 483 $ 3,280 (1) The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company’s common shares at that time, the value of issued share equivalents is based on the market price of the Company’s common shares at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, and the values of forfeited share equivalents and outstanding share equivalents at the end of the period are based on the market price of the Company's common shares at the end of the period. The market price of the Company's common shares was $ 6.79 and $ 8.02 on September 30, 2025 and December 31, 2024, respectively. The change in fair value of the PSUs has been charged to the Condensed Consolidated Statements of Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with PSUs at September 30, 2025 is $ 1.9 million, with $ 1.3 million of this amount included in current accrued liabilities and the remaining portion of $ 0.6 million included in long-term accrued liabilities. The impact associated with the fair value re-measurement of PSUs is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income. The following table summarizes expense associated with the PSUs for the three and nine months ended September 30, 2025 and 2024 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Selling, general and administrative $ 353 $ 619 $ 1,134 $ 1,172 The Company paid cash settlements of $ 1.8 million and $ 1.6 million during the nine months ended September 30, 2025 and 2024, respectively, pertaining to vestings of cash-settled PSUs. Page 22 9. Commitments and Contingencies The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies (“ASC 450”). No less than quarterly, the Company reviews the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. The Company accrues a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to the Company at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Legal Proceedings As previously disclosed, on November 5, 2020, the Company (through its subsidiary Sleep Management LLC) filed a lawsuit against Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (“Vyaire”) in the 15th Judicial District Court for the Parish of Lafayette, Louisiana (the “State Court”) seeking damages for breach of contract and seeking declaratory judgment. The State Court issued an order on September 5, 2023 granting the Company Partial Summary Judgment finding that Vyaire breached the contract. On June 9, 2024, Vyaire and certain of its affiliates filed voluntary bankruptcy under Chapter 11 of the Bankruptcy Code in the US Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). A liquidation analysis subsequently submitted to the Bankruptcy Court disclosed that unsecured claims, including those subordinate to the super-priority claims of certain Vyaire creditors, would not receive any recovery under the proposed Chapter 11 reorganization plan or in the event of a Chapter 7 liquidation. Consequently, collection of the Company's unsecured claim against Vyaire was determined to be not probable. During the year ended December 31, 2024, outstanding funds receivable in the amount of $ 0.9 million related to undelivered respiratory equipment were impaired through Other expense (income). Governmental and Regulatory Matters From time to time the Company is involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way the Company conducts business, loss of licensure or exclusion from participation in government healthcare programs. 10. Income Taxes For the nine months ended September 30, 2025, the Company recorded income tax expense of $ 4.2 million, which includes a discrete tax benefit of less than $ 0.1 million associated with stock-based compensation arrangements. Excluding the impact of the discrete taxes, the effective rate for the nine months ended September 30, 2025 is 31.6 %. The effective rate differs from the amount computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. The Company's effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year. At September 30, 2025 and 2024, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2021 . The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. Page 23 11. Earnings Per Share Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year . Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate. The following reflects the earnings and share data used in the basic and diluted earnings per share computations: Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Numerator - basic and diluted: Net income attributable to Viemed Healthcare, Inc. $ 3,513 $ 3,878 $ 9,295 $ 6,949 Denominator: Basic weighted-average number of common shares 38,638,660 38,870,823 39,190,666 38,803,887 Diluted weighted-average number of shares 40,495,761 40,779,414 41,086,178 40,702,001 Basic earnings per share $ 0.09 $ 0.10 $ 0.24 $ 0.18 Diluted earnings per share $ 0.09 $ 0.10 $ 0.23 $ 0.17 Denominator calculation from basic to diluted: Basic weighted-average number of common shares 38,638,660 38,870,823 39,190,666 38,803,887 Stock options and other dilutive securities 1,857,101 1,908,591 1,895,512 1,898,114 Diluted weighted-average number of shares 40,495,761 40,779,414 41,086,178 40,702,001 Anti-dilutive shares excluded from the calculation consisted of dilutive employee stock options and RSUs that were de minimis in all periods presented. 12. Subsequent Events On October 29, 2025, the Company repaid $ 5.0 million of its 2022 Revolving Credit Facility, reducing the outstanding balance from $ 8.0 million to $ 3.0 million. Page 24